COVID-19-associated hepatic injury differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
TayyabaAli (talk | contribs) No edit summary |
TayyabaAli (talk | contribs) No edit summary |
||
Line 154: | Line 154: | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>+</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>++</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>++</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki> IgG/IgM Antibodies<ref name="pmid32172228">{{cite journal| author=Lippi G, Simundic AM, Plebani M| title=Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). | journal=Clin Chem Lab Med | year= 2020 | volume= 58 | issue= 7 | pages= 1070-1076 | pmid=32172228 | doi=10.1515/cclm-2020-0285 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32172228 }} </ref></nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | | style="padding: 5px 5px; background: #F5F5F5;" align="center" |<nowiki>---</nowiki> | ||
| style="padding: 5px 5px; background: #F5F5F5;" align="left" | | | style="padding: 5px 5px; background: #F5F5F5;" align="left" | |
Revision as of 21:49, 20 July 2020
![](/images/1/16/Home_logo1.png)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Tayyaba Ali, M.D.[2]
Overview
COVID-19-associated hepatic Injury must be differentiated from other conditions that cause elevation of liver enzymes.
Differential Diagnosis
COVID-19-associated hepatic Injury must be differentiated from other conditions that cause elevation of liver enzymes.
Disease | Clinical manifestations | Laboratory findings | Additional findings | |||||||
---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Signs | Transaminitis (elevated AST and ALT) | Viral markers | Autoimmune markers | ||||||
Nausea & vomiting | Abdominal pain | Arthralgia | Jaundice | Hepatomegaly | ||||||
Acute viral hepatitis | Hepatitis A | +++ | ++ | + | +++ | + | +++ | HAV Ab | --- |
|
Hepatitis B | +++ | ++ | ++ | +++ | + | +++ | HBs Ag, HBc Ab, HBe Ag | --- |
| |
Hepatitis C | +++ | ++ | ++ | +++ | + | +++ | HCV Ab | --- |
| |
Hepatitis E | ++ | ++ | +/- | ++ | + | +++ | HEV Ab | --- |
| |
CMV hepatitis | +/- | ++ | - | + | + | ++ | CMV-specific immunoglobulin (Ig)M antibody | -- |
| |
EBV hepatitis | +/- | ++ | - | +/- | + | ++ | Heterophile antibody test, monospot test | -- |
| |
Autoimmune hepatitis | - | + | +/- | ++ | + | +++ | --- | ANA, ASMA, anti SLA/LP, ANCA, ALKM-1 antibodies |
| |
Alcoholic hepatitis | +/- | + | - | + | - | AST>ALT | --- | --- |
| |
Drug induced hepatitis | +/- | + | - | + | + | ++ | --- | --- |
| |
COVID-19-associated hepatic Injury | + | + | - | - | + | ++ | IgG/IgM Antibodies<ref name="pmid32172228">{{cite journal| author=Lippi G, Simundic AM, Plebani M| title=Potential preanalytical and analytical vulnerabilities in the laboratory diagnosis of coronavirus disease 2019 (COVID-19). | journal=Clin Chem Lab Med | year= 2020 | volume= 58 | issue= 7 | pages= 1070-1076 | pmid=32172228 | doi=10.1515/cclm-2020-0285 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32172228 }} </ref> | --- |
|